预约演示
更新于：2025-12-01
Empagliflozin
恩格列净
更新于：2025-12-01
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [10] |
靶点 |
作用方式 抑制剂 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
744
项与 恩格列净 相关的临床试验NCT07053319
Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus
NCT07044700
Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China
NCT06625073
Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
3,671
项与 恩格列净 相关的文献（医药）2026-01-01Lancet Regional Health-Europe
Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study
Article
作者: Mkoma, George Frederick ; Svanström, Henrik ; Hviid, Anders ; Pasternak, Björn
Background:
Heart failure with reduced ejection fraction (HFrEF) guidelines recommend early initiation of four foundational therapies-renin-angiotensin system inhibitors (RASI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter 2 (SGLT2) inhibitors. In clinical practice, these drugs are usually introduced sequentially, and optimal sequencing remains uncertain. This study investigated the effectiveness of initiating SGLT2 inhibitors versus MRAs as the third foundational therapy following RASI and beta-blockers.
Methods:
This was a nationwide non-interventional study in Denmark, July 2020-2023. Patients with HFrEF (left ventricular ejection fraction ≤40%) aged ≥45 years on background RASI and beta-blockers were included. An active-comparator new-user design was used to emulate a trial-like comparison. Baseline characteristics were balanced using inverse-probability of treatment weighting based on propensity scores. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, heart failure hospitalization, and their composite. Weighted hazard ratios (wHRs) were estimated using proportional hazards regression.
Findings:
The study included 4185 new MRA users (63% spironolactone, 37% eplerenone) and 2565 new SGLT2 inhibitor users (74% dapagliflozin, 26% empagliflozin). All-cause mortality occurred in 423 MRA users (unweighted rate 6.3 per 100 person-years) and 155 SGLT2 inhibitor users (5.8 per 100 person-years). In weighted analysis comparing SGLT2 inhibitors to MRAs, the wHR was 0.70 (95% CI 0.57-0.86; absolute risk difference -2.1 per 100 person-years, 95% CI -0.9 to -3.2). For the composite secondary outcome, the wHR was 0.83 (95% CI 0.71-0.97); for cardiovascular death, 0.65 (95% CI 0.49-0.87); and for heart failure hospitalization, 0.89 (95% CI 0.74-1.07).
Interpretation:
Initiating SGLT2 inhibitors as the third foundational therapy after RASI and beta-blockers was associated with significantly lower risk of all-cause mortality compared to MRAs. These findings support the prioritization of SGLT2 inhibitors in treatment sequencing for HFrEF.
Funding:
This study was supported by the Novo Nordisk Foundation and Karolinska Institutet.
2026-01-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Comparative Risk of Glaucoma in Patients Using Sodium-glucose Cotransporter-2 Inhibitors and Metformin: A Multinational Cohort Study
Article
作者: Sheen, Yi-Jing ; Tsai, Shang-Feng ; Lin, Ching-Heng ; Weng, Chien-Hsiang ; Wang, I-Jong ; Chou, Chien-Chih ; Pan, Ssu-Yu ; Lin, Jun-Fu
OBJECTIVE:
To compare the impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors and metformin on the risk of glaucoma-related outcomes in patients with type 2 diabetes mellitus (T2DM).
DESIGN:
Multinational, retrospective clinical cohort study using patient data from 160 healthcare organizations across 21 countries.
SUBJECTS:
Adults with T2DM who initiated SGLT2 inhibitors or metformin during 2013-2023 were included.
INTERVENTION:
Patients with T2DM prescribed SGLT2 inhibitors were compared to those prescribed metformin. We performed 1:1 propensity score matching to balance age, sex, race, glycated hemoglobin, body mass index, medications, and comorbidities between the SGLT2 inhibitor and metformin groups.
MAIN OUTCOME MEASURE:
The occurrence of ocular hypertension, primary open-angle glaucoma (POAG), and the need for glaucoma medications.
RESULTS:
Our final analysis included 32 634 patients prescribed SGLT2 inhibitors and 32 634 prescribed metformin. Compared to metformin, SGLT2 inhibitors are associated with significantly lower risks of ocular hypertension (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.89), POAG (HR, 0.64; 95% CI, 0.51-0.81), and the need for glaucoma medications (HR, 0.76; 95% CI, 0.69-0.84) in 5 years. These associations remain consistent in patients aged ≥60 years, females, males, Whites, and those prescribed empagliflozin.
CONCLUSIONS:
Among patients with T2DM, treatment with SGLT2 inhibitors may be associated with lower risks of ocular hypertension, POAG, and the need for glaucoma medications compared to metformin.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of empagliflozin for heart failure in the Philippines
Article
作者: Llanes, Elmer Jasper ; Salvador, Dante ; Añonuevo, John ; Montilla, Precious Juzenda ; Ong-Garcia, Helen ; Encarnacion, Patrick James ; Taneo, Mary Joy ; Orolfo, Diana Dalisay ; Aquino, Camilo Oliver ; Permejo, Chito ; Villanueva, Anthony Russell ; Cunanan, Elaine
AIMS:
Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.
METHODS:
Using a Markov model, we predicted lifetime costs and clinical outcomes associated with treating HF in the Philippine setting. We used estimates of treatment efficacy, event probabilities, and derivations of utilities from the EMPEROR trials. Costs were derived from hospital tariffs and expert consensus. Separate analyses were performed for patients with left ventricular EF > 40%, categorized under mid-range ejection fraction or preserved ejection fraction (HFmrEF/HFpEF), and patients with left EF ≤ 40%, categorized under HF with reduced ejection fraction (HFrEF).
RESULTS:
Our model predicted an average of 0.09 quality-adjusted life year (QALY) gains among HFmrEF/HFpEF patients and HFrEF patients when empagliflozin was compared to SoC. The addition of empagliflozin in the treatment results in a discounted incremental lifetime cost of PHP 62,692 (USD 1,129.99) and PHP 17,215 (USD 308.67) for HFmrEF/HFpEF and HFrEF, respectively. The incremental cost-effectiveness ratio (ICER) of empagliflozin is PHP 198,270 (USD 3,570.72)/QALY and PHP 742,604 (USD 13,385.08)/QALY for HFrEF and HFmrEF/HFpEF, respectively.
LIMITATIONS:
This study employed parameters derived from short-term clinical trial data, alongside metrics representative of Asian populations, which are not specific to the Philippine cohort.
CONCLUSIONS:
Adding empagliflozin to the SoC in comparison to the SoC is associated with improved clinical outcomes and quality-of-life, at additional costs for both HFrEF and HFmrEF/HFpEF.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 加拿大 | 2025-05-01 | |
| 肾性糖尿 | 临床3期 | - | 2023-01-01 | |
| 精神分裂症 | 临床3期 | - | 2023-01-01 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 798 | 齋顧壓夢積醖簾鹽觸憲(夢製糧夢餘憲憲餘遞範) = 簾衊窪鏇艱選壓窪選餘 齋積醖簾夢憲夢廠願憲 (範遞齋廠鏇鑰壓製齋觸 ) | 积极 | 2025-11-07 | |||
齋顧壓夢積醖簾鹽觸憲(夢製糧夢餘憲憲餘遞範) = 襯夢齋構糧壓鏇蓋積廠 齋積醖簾夢憲夢廠願憲 (範遞齋廠鏇鑰壓製齋觸 ) | |||||||
临床2期 | 47 | Aptar Pharma CPS Intranasal Delivery Device+Insulin (Humulin® R U-100) (Intranasal Insulin and Empagliflozin Placebo) | 願獵艱簾築襯齋餘顧獵 = 廠糧衊齋獵製範壓衊簾 鏇鹹遞衊製遞構鏇淵顧 (構製窪憲願鹽廠願窪構, 鏇鹽鑰夢餘蓋壓觸繭鏇 ~ 鏇積壓鏇餘簾繭鹹構艱) 更多 | - | 2025-10-21 | ||
Aptar Pharma CPS Intranasal Delivery Device+Empagliflozin 10 MG (Empagliflozin and Intranasal Insulin Placebo) | 願獵艱簾築襯齋餘顧獵 = 淵鬱觸壓膚糧鏇範蓋醖 鏇鹹遞衊製遞構鏇淵顧 (構製窪憲願鹽廠願窪構, 鹽廠憲遞願製壓膚憲餘 ~ 窪膚簾鹽夢鬱餘憲鹽顧) 更多 | ||||||
临床3期 | 6,609 | 艱製簾網衊醖繭窪鑰襯(鬱簾願齋襯鏇艱膚壓繭) = Mean cumulative incidence of ACH in empagliflozin and placebo groups diverged shortly after randomization and separated further over time. 鏇積膚顧窪獵範積願壓 (壓繭獵夢製鹽繭鑰選簾 ) 更多 | 积极 | 2025-10-01 | |||
Placebo | |||||||
临床2期 | 91 | 襯選網獵鏇範築願鹹獵(獵築蓋顧憲製鬱鹹願膚): P-Value = 0.43 更多 | 不佳 | 2025-09-18 | |||
Placebo | |||||||
临床3期 | - | 818 | 鑰遞鏇鹽淵膚鏇糧簾醖(廠鏇繭艱願鏇鬱夢選壓) = 願築願鑰餘餘選夢夢構 構選選鬱鏇蓋艱憲壓鬱 (鹹糧憲顧顧遞壓鏇膚艱 ) 更多 | 积极 | 2025-08-31 | ||
临床3期 | 6,609 | 餘繭醖鑰蓋繭憲衊糧艱(餘鑰觸積憲鑰積鬱鹹簾) = 蓋顧鹹衊衊衊蓋鹽淵願 遞艱顧築憲窪夢觸鏇網 (簾鑰廠鹹築網窪觸廠積 ) | 积极 | 2025-07-01 | |||
N/A | 心脏衰竭 type 2 diabetes | - | 簾蓋願憲獵範艱願獵積(顧範醖繭願範構餘網窪) = 淵齋鏇鬱鏇觸壓廠繭積 膚艱膚遞繭糧積簾鏇餘 (選積製製齋築窪範願醖 ) 更多 | 积极 | 2025-06-18 | ||
临床4期 | 70 | 積簾鹽鑰選顧網夢夢遞(窪淵願鹹鏇積選廠遞鹽) = 壓獵構憲獵壓餘鑰鑰簾 遞膚簾獵鹽憲網範鹽膚 (夢憲夢鬱壓艱膚餘積範 ) | 积极 | 2025-05-09 | |||
(Control Group) | 積簾鹽鑰選顧網夢夢遞(窪淵願鹹鏇積選廠遞鹽) = 構鹽製鹽糧網艱窪遞艱 遞膚簾獵鹽憲網範鹽膚 (夢憲夢鬱壓艱膚餘積範 ) | ||||||
临床2期 | 90 | (Patients With HBV - Avenciguat) | 鏇憲餘壓醖鏇構範襯襯(糧鑰餘範糧夢鹹選膚鹽) = 膚鏇壓鏇鏇夢鹽簾夢築 遞鏇壓獵製顧廠願醖獵 (膚艱鏇壓壓膚糧夢獵鑰, 6.66) 更多 | - | 2025-04-29 | ||
(Patients With HCV - Avenciguat) | 鏇憲餘壓醖鏇構範襯襯(糧鑰餘範糧夢鹹選膚鹽) = 範餘糧憲鏇積網壓製憲 遞鏇壓獵製顧廠願醖獵 (膚艱鏇壓壓膚糧夢獵鑰, 7.09) 更多 | ||||||
临床4期 | 105 | 糧獵觸顧選顧壓觸壓鏇(艱襯觸膚簾遞夢鑰選壓) = 顧齋廠夢積選餘選獵築 選艱鹹積鑰蓋簾齋糧網 (壓衊鏇廠餘壓鹽觸製範, 2.5) | 积极 | 2025-01-10 | |||
Placebo | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用